Bidani N, Kirchner P T, Moohr J W, Radkowski M A, Pang E, Cooper M
Clin Nucl Med. 1980 Oct;5(10):450-3. doi: 10.1097/00003072-198010000-00003.
Gallium-67 scan results were correlated with the long-term clinical course in ten children with neuroblastoma. The four patients whose primary tumor did not accumulate gallium have exhibited a significantly better survival time (mean duration 68.2 months) as compared to the six patients with gallium-positive tumors (mean duration 16.6 months, P < 0.001). This difference in survival was not explainable on the basis of accepted prognostic indicators, such as age of patient or stage of disease at initial diagnosis. These results indicate that gallium uptake may be a useful prognostic indicator in children with neuroblastoma, independent of other variables.
对10名神经母细胞瘤患儿的镓-67扫描结果与长期临床病程进行了相关性分析。与6例镓摄取阳性肿瘤患者（平均病程16.6个月，P<0.001）相比，4例原发肿瘤不摄取镓的患者表现出显著更长的生存时间（平均病程68.2个月）。这种生存差异无法根据公认的预后指标来解释，如患者年龄或初诊时疾病分期。这些结果表明，镓摄取可能是神经母细胞瘤患儿一个有用的预后指标，独立于其他变量。
